Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses

Osaka: Takeda has announced that the Company has voluntarily withdrawn the U.S. Biologics License Application (BLA) for its dengue vaccine candidate, TAK-003, following discussions with the U.S. Food and Drug Administration (FDA) on aspects of data collection, which cannot be addressed within the current BLA review cycle.

The future plan for TAK-003 in the U.S. will be further evaluated given the need for travelers and those living in dengue-endemic areas of the U.S., such as Puerto Rico. The vaccine is approved in multiple endemic and non-endemic countries, with more approvals expected over the coming years.

“Our clinical program was designed to account for the complex global nature of dengue, and data from our 4.5-year trial has built confidence in TAK-003’s ability to help provide long-term protection against dengue, with a positive benefit and risk profile regardless of baseline serostatus,” said Gary Dubin, M.D., president of Takeda’s Vaccines Business Unit. “The urgent global need to combat the growing burden of dengue remains, and we will continue to progress regulatory reviews and provide access for people living in and traveling to dengue-endemic areas while we work to determine next steps in the U.S.”

The efficacy and safety profiles of TAK-003 have been demonstrated through a robust clinical trial program, including a 4.5-year Phase 3 study of over 20,000 children and adolescents living in eight dengue endemic areas. The study was designed per World Health Organization (WHO) guidance for a second-generation dengue vaccine, and it considered the need to achieve high levels of subject retention and protocol compliance in endemic regions.

Last year, TAK-003 received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) after going through the EU-M4all process, a parallel review of the vaccine for use in the EU and participating dengue endemic countries around the world. The vaccine has since been approved in the EU, United Kingdom, Brazil, Argentina, Indonesia, and Thailand.

Dengue is a global public health crisis and further prevention measures are needed to support the millions of individuals around the world exposed to dengue.

Takeda's tetravalent dengue vaccine candidate (TAK-003) is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses.

Read also: Taked Dengue Tetravalent Vaccine QDENGA gets European Commission nod

A LOW sperm count, also called oligozoospermia, is where a man has fewer than 15 million sperm per millilitre of semen. Normal sperm densities range from 15 million to greater than 200 million sperm per millilitre of semen. You are considered to...

The Caribbean Heart Institute’s (CHI) team led by CEO and Guyanese born heart surgeon Dr. Gary Stephens, successfully conducted an open-heart surgery utilising cow tissue to reconstruct a patient’s heart, the institution said Tuesday. “This procedure is the first-ever open heart surgery of its kind, to be performed in the country,” CHI added. CHI explained ...

Guyana is still awaiting a reply from the United States Department of Agriculture to several submissions aimed at having that North American country lift an almost six-year old ban on catfish, according to Agriculture Minister Zulfikar Mustapha. With Guyana having recently updated its previous submission, he said the Ministry of Agriculture was awaiting word from ...

Cigna Group's Express Scripts pharmacy benefits unit will add three biosimilar versions of AbbVie's blockbuster arthritis treatment Humira to its list of preferred drugs, the company said on Monday. Reuters Health Information

All such candidates who fulfill the eligibility criteria and are desirous of opting for the sponsored DNB (Post MBBS and Post Diploma) seats 2023 are required to submit their application to the Director of Medical Education, Dept of Health and Family Welfare, Swasthya Bhawan, GN-29, Sector —V, Kolkata -700091. (If they belong to the WIIMES cadre) or Director of Health Services, Dept of Health and Family Welfare, Swasthya Bhawan, GN-29, Sector —V, Kolkata -700091(11 they belong to WBHS or WI3PIIAS cadre).

The submission of the application will be via email at tr.noc.mert@gmail.com for the candidates of WBHS and WBPHAS and via email at wbcounselingcell@gmail.com for the candidates of WBMES in the required format. The circular is already published on the websites www.wbhealth.gov.in and www.wbmcc.nic.in dated 22.3.2023. The applications will have to be submitted by 5:00 pm on 17.7.2023.

Eligibility criteria for Sponsored DNB (Post MBBS) seats –

1. Candidates who are working under the Dept of Health and Family Welfare Govt. of West Bengal on a regular basis are eligible for Sponsored DNB (Post MBBS) seats.

2. Candidates must be in possession of the M1313S degree Certificate recognized by the Indian Medical Council Act 1956 and possess a permanent registration certificate of MBBS qualification issued by the Medical Council of India/ State Medical Council.

3. Must have "Qualified" MEET PG 2023.

Also Read:TN Health Issues Clarification on eligibility for NEET PG, MDS candidates, check out details

Eligibility criteria for Sponsored DNB (Post Diploma) Seats -

1. Candidates who are working under Dept of Health and [Tamil) Welfare Govt. of West Bengal on a regular basis are eligible for Sponsored DNB (Post Diploma) seats.

2. Candidates who have passed the final examination leading to the award of Post Graduate Diploma from Indian Universities, which are duly recognized as per provisions of the Indian Medical Council Act 1956, Govt, of India i.e. have passed final examinations for Postgraduate diploma on or before 31-03-2021 as per provisions of the Trainee Reserve Rules 2015 and its amendments.

3. Candidate must have "Appeared" in DNB-PDCLT 2023.

The physical verification of the candidates shall be conducted from 12 noon till 3 pm on the days as follows: 17-07-2023 till 20-07-2023 (4 days). During such physical verification, the candidate has to attend with the original documents along with the filled-up and duly forwarded proforma as stated above and one set self-attested photocopies of the original documents before the Assistant Director of Medical Education at the Counseling Cell in the ground floor of Swasthya Sathi Building within premises of Swasthya Bhawan (for WBMES cadre) or Assistant Director of Health Services, MERT, in rd floor of B wing at Swasthya Bhawan (if they belong to WBVIS/WBPHAS cadre).

The following documents are required to be placed for verification (original and one set self-attested photocopy) -

1. MEET PG 2023/DNB PDCET 2023 --rank card and admit card

2. Any two of the following valid photo ID (Aadhar card/Voter card/Passport)

3. Age proof (birth certificate/class X admit card/class X certificate)

4. MBBS certificate and final rvIBBS mark sheet

5. Permanent Registration certificate issued by MCIINMC/WBMC

6. Caste certificate (as applicable and issued by the appropriate authority in West Bengal)

7. Non-creamy layer certificate for OBC candidates issued on or after 01.04.2023

8. PwD certificate (as applicable and issued by Medical Board of IPGMER Kolkata)

9. Proof of previous Diploma if acquired (on or before 31.03.2021)

10. Proof of any bond formalities (if applicable, to be completed on or before 31.03.2023)

11. Posting orders and joining reports as proof of regular service

The candidates who fail to submit email on time or fail during verification, or do not attend verification with required documents within the scheduled time, shall not be included in the list for provisional NOC (No Objection Certificate) for Centralized merit-based online counseling for admission to Sponsored DNB seats (Post MBBS and Post Diploma) 2023.

The provisionally eligible candidates shall be handed Provisional NOC on authenticated letterhead, and the scanned copy shall be uploaded to the websites www.wbhealth.gov.in and www.wbmcc.nic.in for public viewing on or after 29.07.2023. It shall also be communicated to NBEMS as per their instructions via email req.cc@natboard.edu.in latest by 31.07.2023. The format of NOC shall be provided by NBEMS in their notice 04.07.2023 on the website www.natboard.edu.in.

The candidates shall bear in mind that this NOC is purely provisional and does not ensure a seal for a particular candidate. The in-service candidates of the Dept. of Health and Family Welfare, Government of West Bengal, must contact respective branch officials to find out whether they are eligible for trainee reserve as per extant rules so that seats are not wasted after allotment, if any.

To view the notice, click on the link below –

https://medicaldialogues.in/pdf_upload/dnb-214034.pdf

Also Read:BFUHS Allocates 95 Seats For BSc Paramedical Courses, Check out Counselling Schedule

PAHO convenes health and foreign affairs authorities for second meeting on future pandemic agreement

Cristina Mitchell

10 Jul 2023

As per the notice, the counselling process of the BSc(H) Nursing program 2023-24 for the following colleges affiliated to IP University will be conducted by the university itself and not by MCC, in reference to Notification no. 30/2023 dated 28.06.2023 issued by GGSIPU.

1. Lakshmi Bai Batra, College of Nursing

2. St. Stephen’s College of Nursing, Tis Hazari, Delhi (Christian Minority)

3. College of Nursing, Hindu Rao Hospital

4. College of Nursing, Kasturba Hospital

5. Panna Dai, College of Nursing, DDU

6. Shakuntala Devi College of Nursing

Also Read:GGSIPU Extends deadline For Registration, Fee Payment, Documents Verification For MBBS, BSc Nursing admissions

However, the counselling for B.Sc(Nursing) courses for the Nursing colleges of VMMC & Safdarjung Hospital and Dr RML Hospital will be conducted by the Medical Counselling Committee of DGHS as done in the previous year along with the following nursing colleges.

1. College of Nursing Florence Nightingale CON, New Delhi

2. College of Nursing LHMC, New Delhi

3. College of Nursing RAK CON, New Delhi, Rajkumari Amrit Kaur College of Nursing

4. College of Nursing Bhopal Nursing College, BMHRC, BHOPAL, Bhopal Memorial Hospital and Research Centre

5. College of Nursing BHU, VARANASI

Bsc Nursing counselling process by IP University:

Documents verification –

Online verification of documents by the University

Closing Date MBBS, BSc Nursing

The candidate claiming benefits under the reserved category has to upload the relevant supporting documents duly issued by Competent Authority.

The candidates may kindly read Admission Brochure to see the details of documents required for being eligible to claim benefits under the Reserved Category and for the ARMY category, please upload Appendix 9(A)/9(B)/9(C) of the Admission Brochure 2023-24.

10.07.2023 (11:50 PM

The candidates note that University's Verifying Officer shall raise queries in cases where the document(s) is deficient or any discrepancy is observed. Candidates are advised to revert back/ upload the required documents immediately to claim the benefit of the reserved category on merit.

The online registration and submission of counselling participation fees for admission in program MBBS and BSc (Hons) Nursing based on the merit of NEET UG 2023 will be in respect of the following medical colleges/institutes affiliated with Guru Gobind Singh Indraprastha University, New Delhi -

MBBS -

1. North DMC Medical College & Hindu Rao Hospital — NDMC (MC), Hindu Rao Hospital, Malkaganj, New Delhi (Admissions to be made against 85% State Quota seats only in respect of candidates who have completed their 11th & 12th class from any school located in the NCT of Delhi).

2. Dr. Baba Saheb Ambedkar Medical College and Hospital, Sector 6, Rohini, Delhi (Admissions to be made against 85% State Quota seats only in respect of candidates who have completed their 11th & 12th class from any school located in the NCT of Delhi)

3. Army College of Medical Sciences, Near Base Hospital, Delhi Gantt., New Delhi (Admissions to be made against 100% sanctioned intake). The admission to the ALMS i.e. Army College of Medical Sciences, is for the children of eligible serving Army personnel, Ex-Army personnel, and war widows/widows of the Army. The children of categories of Army personnel as detailed in Chapter 7. I .4 of the Admission Brochure 2022-23 are eligible, and they are required to upload the relevant certificate Appendix 9 (A), 9(B), 9(C) & 9 (D) as given against the category applicable to them as proof of their eligibility for admission to ALMS.

All the concerned candidates/stakeholders are hereby informed that the admission of 100% seats in the MBBS program at VMMC & Safdadung Hospital, New Delhi, and ABVIMS, Dr. RML Hospital, will be conducted by the Medical Counselling Committee, DGHS. Hence, whosoever is desirous of seeking admission to these 02 affiliated medical colleges/institutes may apply on the website of MCC, DGHS. (https://mcc.nic.in).

BSC (Hons) Nursing –

1. Lakshmi Bai Batra College Of Nursing

2. St. Stephen's College Of Nursing, Tis Hazari, Delhi (Christian Minority)

3. College of Nursing Hindu Rao Hospital

4. College of Nursing Kasturba Hospital

5. Panna Dai College of Nursing, DDU

6. Shakuntala Devi College or Nursing

All the concerned applicants/stakeholders are hereby informed that the admission of 1 00% seats in the BSc (Hons) Nursing program at the College of Nursing, Safdariung Hospital, New Delhi, and College of Nursing. The Medical Counselling Committee, DGHS, will conduct Dr. RML Hospital. Hence, whosoever is desirous of seeking admission to these 02 affiliated medical colleges/institutes may apply on the website of MCC. DGHS. (https://mcc.nic.in).

Eligibility criteria

BSC (Hons) Nursing -

All candidates must appear in the National Eligibility cum Entrance Test — Undergraduate of 2023 (NEET UG 2023) and qualify to be considered for admissions.

Admission terms and conditions -

The minimum qualifying criteria for entrance test to admission to BSc Nursing is as under –

1. General 50th Percentile

2. SC/ST/OBC 40th Percentile

3. General-PwD 45th Percentile

4. SC/ST/OBC-PwD 40th percentile

5. Regarding candidates belonging to SC/ST/OBC, the marks obtained in 3 subjects, Physics, Chemistry, and Biology, shall be 40% individually.

MBBS -

1. Candidate should be an Indian/ Overseas Indian / Nepal citizen. Non-Resident Indians and Foreign Nationals are not eligible.

2. The candidate should be medically fit to pursue the allocated course on medical examination.

3. The candidate should have attained the age of 17 years on or before 31' December of the year of his/her admission to the first year of the Course.

4. No provisional admission will be done for any result awaited or Compartment / Supplementary cases. The admission to the ACMS i.e. Army College of Medical Sciences, is for the children of eligible serving Army personnel, Ex-Army personnel, and war widows/widows of the Army. The children of categories of Army personnel, as detailed in chapter 7.1.4 of the Admission Brochure 2022-23, are eligible. They are required to upload the relevant certificate Appendix 9 (A), 9(B), 9(C) & 9 (D) as given against the category applicable to them as proof of their eligibility for admission to ACMS.

The candidate seeking admission under reserved categories has to mandatorily upload the entitled supporting certificate in his/her name. The Candidates, for further details, must read Chapter 6 (Reservation Policy) of the respective Admission Brochure 2023-24.

In case the candidate is claiming the seat reserved for DSC/DST/DOBC (wherever applicable) category, then He/ She should have passed his/ her qualifying exam from Delhi School/College and must have an SC/ST/OBC certificate issued by the Competent Authority of Govt. of NCT of Delhi only.

Reservation in OBC Category is not applicable for Master's Level and Postgraduate Diploma programs. The OBC category reservation applies only to the University School of Studies and Govt. Colleges (affiliated with GGSIPU) only.

For claiming reservation against the OBC category in Delhi Region, the candidate has to upload a valid OBC category certificate issued by a Competent Authority of Delhi in accordance with the list of OBC categories as per Govt. of NCT of Delhi. And suppose the OBC certificate is issued before 31.03.2023. In that case, it is mandatory for candidates to upload the OBC Non-Creamy Layer certificate, which should be issued after 31st March 2023 with the OBC certificate.

The EWS category reservation applies only to the University School of Studies and Govt. affiliated Colleges. This will be implemented in accordance with the Govt. of India and Govt. of NCT of Delhi orders as applicable. EWS Certificate should be issued after 31st March 2023 stating valid for year 2023-2024.

For claiming a reservation on a seat reserved for DEFENCE Category, the candidate must upload the duly filled and signed Appendix 1 of Admission Brochure 2023-24 issued by the competent authority as mentioned in Admission Brochure 2023-24 along with supporting documents. Reserved Category Candidates who fail to upload documents as per notified schedule or whose documents are not in order will forfeit his/her right to the reserved category claimed and will automatically be converted to General Category as per University rules.

For MBBS only: Candidates claiming a seat in the "Delhi Region" must have passed the qualifying examination (i.e. 11th and 12th ) from any institutes/ Colleges located in Delhi. Allotment of seats in the wrong region on account of incorrect filling of form will lead to cancellation of the allotment at any later stage, and the candidate will automatically lose the right to the seat in his bonafide region if not available at the time of cancellation of seat.

For BSc (Hons) Nursing - Candidates claiming seats in the "Delhi Region" must have passed the qualifying examination from any institutes! Colleges located in Delhi. Allotment of seats in the wrong region on account of incorrect filling of form will lead to cancellation of the allotment at any later stage. The candidate will automatically lose the right to the seat in his bonafide region if not available at the time of cancellation of the seat.

The registration process and counseling fee -

The candidates who have qualified for NEET UG 2023 and have filled online registration form of GGSIPU earlier, and have paid the Non-Refundable Registration Fee of Rs. 1500, such candidates are required to enroll for a centralized online counselling participation fee of Rs 1000 (non – refundable) through Net Banking/Debit Card/Credit Card. The last date to pay was 6.7.2023 up to 11.50 pm.

The candidates who have qualified for NEET UG 2023 and have not filled online registration form of GGSIPU earlier and have not paid the Non-Refundable Registration Fee of Rs. 1500, such candidates are required to register and pay the registration fee of Rs 1500 online and subsequently required to enrol for a centralized online counseling participation fee of Rs 1000 (non – refundable) through Net Banking/Debit Card/Credit Card. The last date to pay was 6.7.2023 up to 11.50 pm.

To view the notice, click on the link below –

https://medicaldialogues.in/pdf_upload/nursing-213866.pdf

Also Read:JIPMER To Conduct 1st Year PG Orientation Program From 19th To 21st July

Diabetes
particularly type 2 diabetes has been increasing in prevalence worldwide. In Jamaica 11.9 per cent of our population above the age of 15 have a diagnosis of diabetes. Diabetes increases the risk of heart disease, and cardiovascular disease is the most common cause of death for the diabetic patient.

Diabetic patients have an increased risk of atherosclerotic disease (that is laying down cholesterol in arteries) and the risks of stroke, coronary artery disease/heart attacks and peripheral vascular disease are all increased in the diabetic population. In addition, diabetics have been shown to an increased risk of heart failure that is not related to atherosclerosis. Given these findings a diagnosis of diabetes suggests the need to find measures to ameliorate these risks. Early studies looking at the treatment of diabetes suggested that lowering of the blood sugar levels over time decreased the likelihood of some of the complications of diabetes. These included the risk of eye disease, kidney disease and nerve disease. Interestingly, these studies did not demonstrate a reduction in the risk of cardiac and vascular disease despite improved diabetic control. Studies found that treatment of hypertension and high cholesterol in the diabetic patient reduced the risk of developing heart disease and for many years this was the primary focus of risk reduction. However, over the past five to 10 years new medications to lower blood sugar have been shown to improve outcomes and to reduce the risk of heart disease.

The improvement in the efficacy of medications available for treatment of diabetes can be traced back to 2008 when the Food and Drug Administration (FDA) in the United States changed the criteria for the approval of medications for diabetes. Prior to this date, it was enough to show that a medication improved glucose control. The experience with rosiglitazone, a medication which effectively lowered blood sugar but at the cost of an increased risk of heart attack and worsening of heart failure, lead to a change in the way in which medications for diabetes were approved. After 2008 companies developing new medications for diabetes needed to show that medications not only lowered blood sugar but that they did not worsen cardiovascular morbidity and mortality. Several classes of medications have been approved under this new standard with the last two groups: the glucagon like peptide agonists (GLP1 agonists) and the sodium glucose co-transport 2 inhibitors (SGLT2 inhibitors) demonstrating the ability to significantly improve cardiac outcome in patients with diabetes.

Currently, physicians who are treating patients with diabetes have several modalities to improve cardiac and vascular outcomes including lifestyle measures, management of additional cardiac risk factors and the use of diabetic medications with the ability to reduce death and disability from cardiac and vascular disease.

Lifestyle measures

All diabetic and cardiac societies advise lifestyle measures for the general population as well as for those diagnosed with diabetes. There is good evidence to suggest that lifestyle measures can help prevent abnormal glucose handling in the body and thus reduce the likelihood of the development of diabetes. Lifestyle measures can also significantly reduce the incidence of associated conditions that worsen cardiac and vascular outcome in the diabetic patient as well as improving outcome in those diabetic patients with heart disease. Dietary measures and exercise have been shown to reduce the incidence of patients with abnormal blood sugars going on to develop type 2 diabetes. They also reduce the risk of hypertension, hyperlipidemia and obesity which increase cardiac risk in the diabetic patient. Studies have also suggested that in patients with established heart disease (including diabetics) diet and exercise can improve cardiac outcome.

Cigarette smoking is one of the most important causes of avoidable death worldwide and significantly worsens the risk of heart and vascular disease in the diabetic patient. From the point of view of the heart and blood vessels any amount of smoking (even second-hand smoke) serves as a spur to vessel damage and the laying down of cholesterol in arteries. Obesity is prevalent in the Jamaican population (55.5 per cent of Jamaican adults). Obesity not only increases the risk of type 2 diabetes itself, but also increases several cardiac risk factors and the incidence of heart disease including heart failure and coronary artery disease. Good sleep hygiene, avoiding/limiting alcohol, not using illicit drugs and stress management all play important roles in improving long term cardiac and vascular outcome in all populations including diabetics.

Treatment of hypertension in diabetes

Hypertension and Diabetes (particularly Type 2 diabetes) frequently coexist. They have several risk factors in common including obesity, inactive lifestyle, family history etc. They also have several shared hormonal and metabolic abnormalities. Hypertension is twice as common in the diabetic population as compared to the general population. Hypertension and type 2 diabetes together increase the risk of increase heart enlargement, stroke and heart failure more than either condition alone. Many studies have demonstrated the importance of treating hypertension to reduce risk, with greater benefits being noted in the population with type 2 diabetes. One study found that lowering the systolic blood pressure by an average of 5.6mmHg lowered the risk of cardiovascular death by 18 per cent. A large meta-analysis of studies including approximately 79000 patients found that lowering the systolic blood pressure to less than 130 mmHg lowered the risk of stroke by 39 per cent. Evidence has been found that treating hypertension in diabetic patients lowers the risk of severe kidney disease, heart failure, eye disease. Most major diabetic societies suggest targeting blood pressures less than 130 systolic and less than 80 diastolic to improve outcome.

Treatment of high cholesterol in diabetes

Cholesterol abnormalities are common in diabetes. The most common findings are an increase in the triglycerides and a lowering of the HDL (good cholesterol). The LDL (bad cholesterol) is usually not significantly elevated but the type of LDL particles that are found in the diabetic patient may be more likely to result in heart and vascular disease. There is a substantial body of evidence that using statin drugs in diabetes improves outcome. There is some debate among the cardiac and diabetic societies as to when to treat, how aggressively to treat and what the goals of treatment should be. In general diabetics between the ages of 40-75 with risk factors for vascular disease or established vascular disease should be on statin therapy. The American College of Cardiology and the American Diabetes Association propose that all diabetes between the ages of 40-75 should be treated regardless of baseline cholesterol.

In our next article we will look at the impact of diabetic medications on the cardiovascular outcome of the diabetic patient.

Dr Ernest Madu, MD, FACC and Dr Paul Edwards, MD, FACC are consultant cardiologists for the Heart Institute of the Caribbean (HIC) and HIC Heart Hospital. HIC is the regional centre of excellence for cardiovascular care in the English-speaking Caribbean and has pioneered a transformation in the way cardiovascular care is delivered in the region. HIC Heart Hospital is registered by the Ministry of Health and Wellness and is the only heart hospital in Jamaica. Send correspondence to info@caribbeanheart.com or call 876-906-2107.